Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Open-Label, Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00072722 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00072722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00072722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Open-Label, Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
Lead sponsor
Celgene Corporation
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2003
Completion date
April 30, 2005
Enrollment
36
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer